Extended-Release Buprenorphine Not Necessarily Cost-Effective

TUESDAY, Sept. 19, 2023 -- For patients with opioid use disorder (OUD), treatment with extended-release buprenorphine is not cost-effective when transmucosal buprenorphine is available, according to a study published online Sept. 13 in JAMA Network...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Study